Royalty Report: Drugs, Pharmaceuticals, Therapeutic – Collection: 3797

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Therapeutic
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3797

License Grant
Under the revised License Agreement, the Licensee will receive an exclusive license to develop and commercialize ten products (brandable pharmaceutical products that qualify for filing with the United States Food and Drug Administration  under a 505(b)(2) application and ten generic products (generic bio-equivalents of branded products which qualify for filing with the FDA pursuant to an Abbreviated New Drug Application) under the Nostrum Technology within a three year period.

IPSCIO Record ID: 7086

License Grant
The Licensee received an exclusive worldwide License to develop and commercialize ten 505(b)(2) products (brandable pharmaceutical products that qualify for filing with the United States Food and Drug Administration) and ten generic products (generic bio-equivalents of branded 7 products which qualify for filing with the FDA pursuant to an Abbreviated New Drug Application) under the Licensor Technology within a three year period.
Field of Use
The Licensee is a pharmaceutical company focusing on the development of oral controlled-release drug formulations utilizing proprietary drug formulations and delivery technologies.  The rights granted apply to the healthcare industry.

IPSCIO Record ID: 4285

License Grant
Licensor hereby grant to Licensee a non-exclusive, royalty-bearing, non-transferable  and non-sublicensable license to the Licensed Patents to make, have made, import, use, sell, and offer for sale Licensee's Generic Product in the Territory solely during the License Term.
License Property
Licensed Patents means any and all patents now and in the future owned, controlled, assigned, or licensed to Licensor that are necessary for Licensee to make, have made, use, import, sell and offer for sale, Licensee's Generic Product in or for the Territory, including, but not limited to the '529 patent, '510 patent, '333 patent, '334 patent, '263 patent and '790 patent, and any current and future continuations, continuation-in-parts, divisionals, reexaminations, and/or reissues of such patents.  

Generic Product means (i) a generic equivalent of the Brand Product approved under an Abbreviated New Drug Application or pursuant to an application under 21 U.S.C. § 355(b)(2), including Licensee's Generic Product, or (ii) an AG Product.  

Brand Product means the product that is approved for distribution and sale under the Brand Product NDA and sold under the trademark Lidoderm® or any successor trademark.  

Brand Product NDA means New Drug Application No. 20-612 and any amendments or supplements thereto.

Licensee's Generic Product means Lidocaine Patch 5% that is the subject of Licensee's ANDA, and all amendments and supplements thereto, and which is intended to be AB-rated to the Brand Product.  

AG Product. The license granted pursuant to Section 2(a) shall be partially exclusive for a period of time in that Licensor and their respective Affiliates shall not market or sell a Generic Product, or authorize or license a Third Party to market or sell an AG Product at any time before the earlier of (i) seven and a half (7.5) months from the Start Date, and (ii) the Launch of any Third Party Generic Product in the Territory.

AG Product means a generic version of the Brand Product that is manufactured and sold under the Brand Product NDA without a trademark or using a trademark other than Lidoderm® or a successor trademark thereto.  

Sub-Licenses. Licensee shall have the right to sub-license the license granted to its Affiliates, but not to any Third Party, provided that any such sub-license shall be subject to Licensor's prior written consent, not to be unreasonably withheld or delayed.

Licensee seeks approval to manufacture, market and sell Licensee's Generic Product before the expiration of United States Patent No. 5,827,529 (the '529 patent), United States Patent No. 5,741,510 (the '510 patent), United States Patent No. 6,096,333 (the '333 patent), United States Patent No. 6,096,334 (the '334 patent), United States Patent No. 5,536,263 (the '263 patent), and United States Patent No. 6,361,790 (the '790 patent).

In response to the filing of Licensee's ANDA, Licensor filed suit against Licensee in the United States District Court for the District of Delaware alleging infringement of the '529 patent.

Licensor also filed suit against Licensee in the United States District Court for the District of Delaware alleging infringement of the '510 patent, the '333 patent, and the '334 patent.

No Party admits liability, but each desires to resolve, compromise and settle the Litigation on the terms and conditions set forth herein.

Field of Use
Licensee has filed Abbreviated New Drug Application (ANDA) No. 20-675 with the United States Food and Drug Administration (FDA) seeking approval to manufacture, market, and sell Licensee's Generic Product, which product is intended to be an AB-rated generic version of Licensor's drug product Lidoderm®.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.